Semaglutide vs Tirzepatide: Molecules, Evidence, Genetics

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetics behind every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with Novo Nordisk or Eli Lilly.

Put semaglutide and tirzepatide next to each other and the differences start at the molecule and ripple outward to indications, dosing, trial design, and price. This head-to-head, current as of April 2026, walks the two compounds side by side and closes on the inherited biology that applies no matter which one a clinician chooses.

Two molecules, two receptor targets

Semaglutide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist sold under the brand names Ozempic, Wegovy, and Rybelsus, and also available through licensed compounding pharmacy pathways. Tirzepatide is a GIP and GLP-1 dual receptor agonist marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, likewise available through licensed compounding pathways. Both act on the pancreas, hypothalamus, and gut to slow gastric emptying and raise satiety; tirzepatide's added agonism at the GIP receptor is the defining molecular split between them. In practice, that second receptor is why tirzepatide is often described as a dual incretin agent rather than a straightforward GLP-1 drug.

Approved indications side by side

Semaglutide reached FDA approval for type 2 diabetes first (Ozempic, 2017), followed by oral Rybelsus for diabetes (2019) and Wegovy for chronic weight management (2021). Tirzepatide arrived as Mounjaro for type 2 diabetes (2022), then Zepbound for chronic weight management (2023), with an expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). Which indication a prescription is written under drives both eligibility and insurance treatment.

What the head-to-head data shows

Semaglutide's record runs through the SUSTAIN, STEP, and PIONEER programs; tirzepatide's through SURPASS for diabetes and SURMOUNT for weight and sleep apnea. A direct comparison exists: SURPASS-2 evaluated tirzepatide against semaglutide 1 mg in type 2 diabetes. Because trial populations, doses, and primary endpoints differ, the honest read is per-trial rather than a blanket winner declaration across every use case. Indirect comparisons across separate weight-management programs are informative but cannot replace a purpose-built head-to-head, so clinicians read them cautiously.

Shared safety signals

Both compounds carry the GLP-1 class boxed warning for thyroid C-cell tumor risk observed in rodent studies. The most common side effects across both are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually most intense during dose escalation. Serious events reported in both classes include pancreatitis, gallbladder disease, and acute kidney injury in the setting of dehydration.

Cost at the pharmacy counter

Semaglutide list pricing varies by brand and pharmacy as of April 2026; see the individual brand pages for current numbers. Tirzepatide runs approximately $1,059–$1,069 per month at U.S. list price as of April 2026 (Eli Lilly published pricing for Zepbound and Mounjaro). Out-of-pocket cost then swings on insurance coverage, the indication on the prescription, manufacturer savings cards, and whether a compounded alternative is available through a licensed pathway. The gap between list price and actual out-of-pocket cost is often wide, which is why the sticker figure rarely reflects what a given patient pays.

The genetics that sit beneath both

Whichever molecule wins the clinical argument, the upstream architecture is shared. Variants in GIPR, FTO, and MC4R influence baseline appetite regulation, satiety signaling, and incretin biology — GIPR in particular shapes the GIP arm that tirzepatide engages. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights spanning these genes. It does not predict response to either compound; it maps the terrain each one has to work on.

PlexusDx offers semaglutide through its Weight Management Protocols, including the Semaglutide Injection protocol. The differentiator is that upstream genetic context — the test-before-you-invest approach that turns a comparison into an informed conversation with your provider.

Related reading on PlexusDx: Novo Nordisk Ozempic, Ozempic Strength, Ozempic and Wegovy, Ozempic Company.

Frequently Asked Questions

What is the core mechanical difference between the two?

Semaglutide is a GLP-1-selective receptor agonist, while tirzepatide is a dual GIP and GLP-1 receptor agonist. The practical distinction is whether the molecule engages one incretin receptor or two — tirzepatide adds GIP activity. Both still slow gastric emptying and increase satiety signaling through the shared GLP-1 pathway.

Which one produces more weight reduction?

Trial populations, doses, and endpoints differ, so the cleanest answer is per-trial. SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes; weight-management studies used separate designs. Individual response varies, and the upstream genetic pathway applies to both regardless of which is prescribed.

Are their side-effect profiles different?

The profiles are broadly similar across the GLP-1 class, with gastrointestinal symptoms most common during dose escalation. Some trials show slightly higher rates of certain GI effects with tirzepatide. Both carry the class boxed warning for thyroid C-cell tumor risk seen in rodent studies — discuss your full history with a provider.

Does the genetic test predict which compound suits me?

No. The Precision Peptide Genetic Test never predicts response to semaglutide, tirzepatide, or any drug, and never reads drug response. It analyzes pathway-level variants in GIPR and FTO, and MC4R that shape baseline GLP-1 biology — the upstream variable that holds whichever compound a clinician recommends.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.